Biogen Inc. stock underperforms Thursday when compared to competitors
Biogen Inc. closed 41.04% below its 52-week high of $238.00, which the company achieved on July 12th.
Biogen: Balancing Risks And Opportunities
Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...
Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead.
Jefferies analysts singled out the stocks that will be affected the most and the least by potential import taxes.
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.
The Harvard Crimson20h
Biogen to Move Global Headquarters to Kendall Commons in 2028
Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new ...